[克罗恩病 - - 欧洲新治疗指南]
Teresa Hof1, Hannes Neeff2, Peter Hasselblatt1
1Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Freiburg.
Deutsche medizinische Wochenschrift (1946)
|October 28, 2025
概括
欧洲克罗恩氏病和结肠炎组织 (ECCO) 更新的指南建议对克罗恩氏病进行多学科的护理和针对性治疗策略. 像TNF和IL-23抗体这样的先进疗法比传统治疗更好,以获得更好的结果.
科学领域:
- 胃肠病学 胃肠病学
- 临床治疗学 临床治疗学
- 炎症性肠道疾病管理管理
背景情况:
- 克罗恩病的管理需要更新治疗指南.
- 目前的治疗方法在有效性和长期结果方面存在局限性.
研究的目的:
- 批判性地审查克罗恩病目前的医疗和外科治疗选择.
- 为优化患者护理和治疗终点提供基于证据的建议.
主要方法:
- 对克罗恩病治疗方法的现有文献进行系统审查.
- 对药物的疗效,副作用概况和外科手术的分析.
- 收录了欧洲克罗恩氏和结肠炎组织 (ECCO) 的专家意见.
主要成果:
- 传统的治疗方法,如5-氨基酸盐和皮质类固醇,其作用有限.
- 提奥普林因副作用和效率低于infliximab而需要谨慎使用.
- 突出的是先进疗法 (TNF抗体,IL-23抗体) 和营养干预措施.
- 早期的手术干预,特别是腹腔镜,可以预防长期并发症.
结论:
- 多学科团队和治疗到目标的方法对于克罗恩病的管理至关重要.
- 建议对先进疗法进行个性化选择.
- 营养疗法和早期的手术选择需要更多的考虑.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
425
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
425
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478
Inflammatory Bowel Disease IV: Pharmacological Management
471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
471
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
631
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
631
Drugs for Treatment of Ulcerative Colitis in IBD
449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449


